Is Nivolumab Only Administered Intravenously?
Yes, nivolumab (brand name Opdivo) is approved solely for intravenous (IV) administration. It is infused over 30 minutes every 2, 4, or 6 weeks, depending on the dose and cancer type treated, such as melanoma, lung cancer, or renal cell carcinoma.[1]
Why No Subcutaneous or Oral Option?
Nivolumab is a monoclonal antibody that requires IV delivery to ensure proper absorption and bioavailability. Subcutaneous formulations are not approved, as clinical trials have not demonstrated equivalent efficacy or safety via other routes. Attempts to develop subcutaneous versions face formulation challenges with large-molecule biologics like PD-1 inhibitors.[1][2]
How Is the IV Infusion Done?
Dosing starts at 240 mg every 2 weeks or 480 mg every 4 weeks for most indications. Premedication is rarely needed, but infusion reactions occur in under 5% of patients. It's given in outpatient settings, taking about 30 minutes after the first cycle.[1]
What Happens with Dosing Errors or Missed Infusions?
If delayed, administer as soon as possible without exceeding the next scheduled dose. No data supports home administration or self-injection; it must be by healthcare professionals.[1]
Any Subcutaneous Alternatives or Competitors?
No subcutaneous nivumab exists. Competitors like pembrolizumab (Keytruda) are also IV-only, though subcutaneous atezolizumab (Tecentriq) is approved for some uses. Biosimilars remain IV.[1][2]
Patent Status for Nivolumab Formulations
Core patents on IV nivumab expired or face challenges, but no subcutaneous patent applications are listed. Check DrugPatentWatch.com for updates on formulation patents.[3]
[1] Opdivo (nivolumab) prescribing information, Bristol Myers Squibb.
[2] FDA Orange Book approvals for PD-1 inhibitors.
[3] DrugPatentWatch.com - Nivolumab patent dashboard.